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Abstract
Aim
To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes
with choroido-retinal vascular diseases.
Design
Prospective, randomised, double blind, interventional study.
Methods
Twenty patients with centre involving macular oedema in diabetic retinopathy, retinal vein
occlusion, and neovascular age-related macular degeneration were assigned to 2 groups
receiving 3 doses of 1.25mg/0.05ml (group 1) and 2mg/0.08ml IVZ (Group 2) at 4 weekly
intervals. Safety data was collected after 30 minutes, 1 and 7 days, and 4, 8 and 12 weeks
after injection. Changes in continuous variables were compared using paired t-test and cate-
gorical variables were compared using chi-square test of proportions. Repeated-Measures
ANOVA with nesting test was used to compare variations in continuous variables by IVZ
dose over time. Primary outcome measures were ocular and systemic adverse events at 4
weeks.
Results
Eleven females and nine males, with mean age of 63.2± 7.3 years were included. Ocular
adverse events included subconjunctival haemorrhage in 1 eye, intraocular pressure (IOP)
>21mmHg at 30 minutes in 6 eyes and mild pain in 3 eyes at 1-day. There was no significant
difference in IOP rise between the 2 groups at 30 minutes (p = 0.21). No other ocular or sys-
temic adverse events were observed. There was significant improvement in the best cor-
rected visual acuity (LogMAR) from 0.95±0.6 to 0.6±0.4 (p<0.01) and 0.47±0.3 (p<0.01),
PLOS ONE | https://doi.org/10.1371/journal.pone.0223944 October 24, 2019 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Braimah IZ, Kenu E, Amissah-Arthur KN,
Akafo S, Kwarteng KO, Amoaku WM (2019) Safety
of intravitreal ziv-aflibercept in choroido-retinal
vascular diseases: A randomised double-blind
intervention study. PLoS ONE 14(10): e0223944.
https://doi.org/10.1371/journal.pone.0223944
Editor: Gianni Virgili, Universita degli Studi di
Firenze, ITALY
Received: November 6, 2018
Accepted: September 29, 2019
Published: October 24, 2019
Copyright: © 2019 Braimah et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper. Additional data which include
patients fundus photographs, optical coherence
tomography and fluorescein angiograms, cannot
be shared publicly for ethical reasons because they
contain identifying information. The Korle-Bu
Teaching Hospital IRB has imposed restriction on
sharing of these images in compliance with the
data protection act of Ghana. Interested, qualified
researchers may direct their data queries to the
principal investigator through the following email
address: izbraimah@ug.edu.gh.
reduction in central subfield foveal thickness from 405.9±140 um at baseline to 255.6±75
um (p<0.01) and 238±88 um (p<0.01) at 4 and 12 weeks respectively, although no differ-
ence was observed between the 2 groups (p = 0.34).
Conclusion
IVZ at 1.25mg and 2mg had similar safety profiles, and did not have any major unexpected
adverse events. Further studies with larger cohorts are required to confirm efficacy.
Introduction
Retinal and choroidal vascular diseases such as diabetic macular oedema (DMO), neovascular
age-related macular (nvAMD), and macular oedema (MO) following retinal vein occlusions
(RVO) are a significant cause of visual impairment in developed countries. They are increas-
ingly becoming important causes of blindness in developing and low-middle income countries
including Ghana [1–3]. Vascular endothelial growth factor, which promotes angiogenesis and
increases vascular permeability, has been found to play an important role in the pathogenesis
of these diseases [4–6]. Ranibizumab (Lucentis; Genentech, San Francisco, California, USA/
Novartis, Basel, Switzerland) and aflibercept (Eylea; Regeneron, Tarrytown, New York, USA)
have been approved by the USA Food and Drugs Agency (FDA) and European Medicines
Agency (EMA) for the treatment of DMO, nvAMD and MO following RVO. Bevacizumab
(Avastin, Genentech Inc. USA /Roche, Basel, Switzerland) and ziv-aflibercept (Zaltrap, Sanofi-
Aventis US, LLC, Bridgewater, New Jersey, USA and Regeneron Pharmaceuticals, Inc., Tarry-
town, New York, USA) have been approved by the US FDA and EMA for the treatment of
colorectal cancers [7]. Unfortunately, ranibizumab and aflibercept are expensive (US $1950
and $1850 per dose respectively) and many needy patients in developing countries including
Ghana lack the funds to pay for these treatments which are self-funded. The unavailability of
rebranded equivalents for poorer countries has compounded the problems in sub-Saharan
Africa.
Bevacizumab (off-label use) is the most commonly used anti-VEGF worldwide. This is par-
ticularly so in the developing world, where its cost-effectiveness when compounded is of eco-
nomic benefit in the treatment of retinal vascular diseases [8]. Due to individual variability in
their response to a particular anti-VEGF the availability of alternative agents that are of similar
cost to bevacizumab will be useful particularly in patients who are recalcitrant or ‘poor
responders’ or ‘non-responders’ to bevacizumab [9]. Short-term and a few long-term reports
have shown that the 1.25 mg dose of ziv-aflibercept (off-label use) was safe and effective in
patients with DMO, nvAMD and MO following RVO [10–18]. Chhablani et al have reported
that the 2mg dose of intravitreal ziv-aflibercept (IVZ) was safe and effective at 4 weeks after
single injection [19]. A recent retrospective study (Singh et al, 2018) reported on the safety of
IVZ in a large number participants [20].
There is no data on the safety and efficacy of IVZ in sub-Saharan Africa including
Ghana to date, except for a few inclusions in the recent retrospective study of Singh et al
(2018) [20]. This study evaluated the safety of 2 doses of ziv-aflibercept administered intravi-
treal injection in a randomised trial in Ghanaian patients with choroido-retinal vascular
diseases.
Intravitreal ziv-aflibercept in retinal vascular diseases
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Materials and methods
This prospective randomized double-blind intervention study was conducted at the Eye Cen-
tre of Korle-Bu Teaching Hospital (KBTH) from December 2017 to March 2018. The study
protocol received approval from Institutional Review Board of KBTH and Food and Drugs
Authority (FDA) of Ghana (FDA/CT/174) and was registered at the Pan African Clinical Trial
Registry (www.pactr.org) database (PACTR201701001940111). The study adhered to the
Ghana Data Protection Act, and the tenets of declaration of Helsinki on human subjects. The
study was monitored by a Data and Safety Monitoring Board, and the FDA of Ghana. Details
of our study protocol have been deposited in protocols.io, dx.doi.org/10.17504/protocols.io.
2dwga7e.
Recruitment and eligibility
Consecutive patients with clinical diagnosis of DMO, nvAMD and MO following RVO were
recruited into the study after obtaining written informed consent. Patients were eligible for the
study if they met the following criteria: age 18 years or older, diagnostic criteria for DM, RVO
and active nvAMD, treatment naïve patients, understand and willing to sign consent form, abil-
ity to comply with clinic visits, centre-involving MO in patients with diabetes mellitus and RVO
with retinal thickness>300um using SD- OCT and, best corrected visual acuity (BCVA) of 6/12
(Snellen) (LogMAR 0.3) or worse. Exclusion criteria were glaucoma or IOP>21mmHg, intraoc-
ular surgery within 3 months in the study eye, history of uveitis, pregnancy or breastfeeding
mothers, renal failure on dialysis or previous kidney transplant, allergy to active drug or excipi-
ents, cardiovascular events such as myocardial infarction or cerebrovascular accident, eye infec-
tions such as blepharitis, dacryocystitis, conjunctivitis or keratitis, and myopia�-6.0 Dioptres.
Medical history was taken from eligible patients including age, sex, history of hypertension,
DM, hyperlipidaemia, cigarette smoking, current medications, duration of eye symptoms,
diagnosis and any previous treatments. Comprehensive ocular examinations including: BCVA
measurement using a standardised Early Treatment Diabetic Retinopathy Study (ETDRS)
visual acuity chart (Precision Vision, La Salle, Illinois, USA) and recorded as logarithm of min-
imum angle of resolution (LogMAR), intraocular pressure (IOP) measured using Goldmann
applanation tonometer, slit lamp biomicroscopy (Haag Strait model 900) examination of the
anterior segment, and posterior segment examination with the aid of Volk 90D or 78D lenses.
If both eyes were eligible, only the eye with the worse BCVA was recruited into the study. The
other eye received standard care at a different visit. All patients had colour fundus photogra-
phy (CFP) (Zeiss 450 Fundus Camera, Zeiss Inc. Jena, Germany), fundus fluorescein angiogra-
phy (FFA) (Zeiss 450 Fundus Camera, Zeiss Inc. Jena, Germany) and spectral domain optical
coherence tomography (SD-OCT) (Topcon 2000, Tokyo, Japan) at baseline. Systemic arterial
blood pressure, fasting lipids and fasting blood sugar were also measured at baseline. The
sphygmomanometer (Blanket MK-3, Accoson, England), SD-OCT and fundus camera were
calibrated by Ghana Standard Authority prior to the commencement of the study.
Randomization. Eligible patients were randomly assigned to either 1.25mg (Group 1) or
2mg (Group 2) ziv-aflibercept using simple random sampling by a physician independent of
the masked study investigators and the assigned dose of ziv-aflibercept was concealed to both
patients and the masked trial (examining) ophthalmologists. Each patient received identical
treatments at all treatment visits as per the original randomisation.
Preparation of intravitreal ziv-aflibercept
The vial containing 100mg/4ml of ziv-aflibercept was punctured once under the laminar air
flow system at the pharmacy manufacturing unit of KBTH and withdrawn using 5μ microfilter
Intravitreal ziv-aflibercept in retinal vascular diseases
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in 0.15ml aliquots into 1 ml syringes, labelled and each syringe kept in separate sterile plastic
pouch (Eye Drape plus, Aurolab, India) and were immediately stored at 4 degrees Celsius.
Two (2) syringes containing the withdrawn samples were cultured on chocolate agar. Negative
culture report was received before the remaining samples were released for injection and were
used within 2 weeks from the date of preparation.
Intravitreal injection. This was performed by a certified physician who was independent
of the masked clinical investigators. Standard precautions relating to intravitreal injections
were observed. Intravitreal injections were given in the operating theatre using a sterile tech-
nique. Topical anaesthetic agent proparacaine and 5% povidone iodine were instilled into the
conjunctival cul-de sac and periocular skin, eyelids and lashes cleaned using 10% povidone
iodine. The eye was draped, 5% povidone instilled and the injection given in the inferotem-
poral quadrant using half inch 30-gauge needle into the mid vitreous cavity at 4 mm or 3.5mm
posterior to the limbus in phakic and pseudophakic eyes, respectively and 5% povidone iodine
was further instilled at the end of the procedure. Hand motion vision was checked and con-
firmed to be present. No topical antibiotics were given prior to, during or after each injection.
IOP was measured 30 minutes post injection using Goldmann applanation tonometer. The
intravitreal injections were repeated at 4 weeks and 8 weeks.
Follow-up examinations
Occurrence of ocular and systemic adverse events were assessed, and BCVA, IOP and slit lamp
biomicroscope examination of the anterior and posterior segment were done on day 1 and 7
post initiation injection, and at 4 weeks, 8 weeks and 12 weeks. SD-OCT and fundus photogra-
phy were done at all visits with the exception of day 1 post-injection. Fasting blood sugar and
lipids were repeated on day 1 and 7 post-injection. The flow of participants through the study
is shown in Fig 1.
Image grading/analysis
Automated read outs from OCT scans (including retinal thickness) were recorded by examin-
ing masked local investigators. Anonymised CFP, FFA and SD-OCT were submitted electroni-
cally analysed by a remote masked independent investigator who was a trained retinal
specialist (WMA) with expertise in retinal image grading. Any disparity in grading, as neces-
sary, were to be adjudicated by a panel of 3 investigators (WMA/IZB/KAA).
Outcome measures
The primary outcome measure in this study was safety of IVZ at 4 weeks. Ocular toxicity was
assessed based on the number of ocular adverse events such as blurred vision (mild- loss of 0.1
LogMAR, moderate- loss of 0.2 LogMAR and severe—� 0.3 LogMAR), eye pain, raised intra-
ocular pressure (>21mmHg), subconjunctival haemorrhage, conjunctival hyperemia, corneal
abrasions, cataract, intraocular inflammation and endophthalmitis, retinal tears and retinal
detachment, and deterioration of SD-OCT parameters including CSFT.
Intraocular inflammation/endophthalmitis was assessed using the standardised uveitis
nomenclature (SUN) working group classification [21]. The definitive proof of endophthalmi-
tis was dependent on vitreous biopsy and microbiological evaluation (microscopy, culture).
Eye pain was assessed using the eye sensation scale [22].
Systemic adverse events were assessed based on systemic evaluation for the presence of
hypertension, fever, gastrointestinal (GI) disorders, infections, neurologic disorder, Antiplate-
let Trialists’ Collaboration (APTC) events including non-fatal myocardial infarctions,
Intravitreal ziv-aflibercept in retinal vascular diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0223944 October 24, 2019 4 / 15
congestive heart failure, hospitalization and deaths, using predesigned questionnaire. Confir-
mation of systemic adverse event was done by the study physician.
Secondary outcome measures were occurrence of ocular and systemic adverse events at 12
weeks, IOP>25mmHg or increased IOP> 10mmHg from baseline, change in BCVA (Log-
MAR), CSFT and SD-OCT at 4 and 12 weeks from baseline.
The severity of ocular and systemic adverse events was determined using a toxicity grading
scale and were categorised into mild, moderate, severe, potentially life threatening and death
(S1 Table).
Fig 1. Flow of participant through the study.
https://doi.org/10.1371/journal.pone.0223944.g001
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Study monitoring
Monitoring for this study was done by a 3-member data and safety monitoring board and
the Ghana FDA, to ensure that the rights and well-being of the enrolled patients were
protected, that the reported trial data were accurate, complete, and verifiable, and that the con-
duct of the trial was compliant with Good Clinical Practice and with applicable Ghana FDA
requirements.
Statistical analysis
All statistical analyses for this study was done using STATA 13 (Statacorp, Texas, USA). The
frequencies of ocular and systemic adverse events and serious adverse events were computed.
Continuous variables were presented as mean and standard deviation (SD). Pre- and post-
injection changes in BCVA, IOP, and CSFT were compared using paired t-test and categorical
variables were compared using Fisher’s exact test or chi-square. Repeated-Measures ANOVA
with nesting test was used to compare variations in continuous variables by IVZ dose, over
time as well as interaction between IVZ dose and over time at times 0, 30 minutes post initia-
tion of injection, day 1 and 7, and 4, 8 and 12 weeks. A p value<0.05 was considered statisti-
cally significant.
A standard study size of 8 eyes per dose has a 95% probability of detecting adverse events at
a true rate of�32% at the specific dose. As such, if a specific particular adverse event is not
observed in the 8 participants, there is a 95% confidence that the rate for the particular event at
the specified dose is<32%. A sample size of 10 per group was chosen to allow for any potential
drop out at study completion. All randomised subjects who received any study treatment and
had at least 1 post-baseline BCVA in the study eye were included in full analysis set.
Results
A total of 20 eyes (10 in group 1) of 20 treatment naïve patients who received IVZ and followed
up for 12 weeks were included in this study. Their mean age (±Standard deviation) was 63.2±
7.37 years, and included 11 females. The main presenting complaint were blurred vison (18
patients) and metamorphopsia (2 patients) and the median duration of symptoms was 90 days
(interquartile range, 60–112.5). The following systemic co-morbidities were observed: hyper-
tension (17), diabetes mellitus (11), hyperlipidemia (2) and sickle cell disease genotype SS (1).
Five patients consumed less than eight units of alcohol per week, and none smoked cigarette
previously or currently. Eighteen eyes were phakic and 2 pseudophakic. The diagnosis
included DMO (6), active nvAMD (7) and MO associated with RVO (7). The baseline clinical
characteristics of the 2 groups were similar (Table 1).
Adverse events
Three patients (2 in group 1) reported eye pain of grade 2 (mild) severity on day 1 visit post
injection. The pain resolved without treatment. No incidence of eye pain was reported in sub-
sequent visits. Subconjunctival haemorrhage (1 eye in group 1), raised IOP>21mmHg at 30
minutes post-injection (5 eyes [50%] in group 2, 1 eye [20%] in group 1) were observed. IOP
rise was graded as mild (grade 1) in all eyes because no eye had IOP rise>10mmHg from base-
line. No treatment was given for the raised IOP and reverted to normal by day 1 after the initial
injection. No eye had IOP>21mmHg on subsequent visits (Table 2).
Variation in average IOP (± SD) was statistically significant over time (p<0.01); however,
there was no significant variation between the IVZ dose and interaction (IVZ dose and time).
The overall average IOP (± SD) for the whole study period was 15.8 ± 3.7. Although there was
Intravitreal ziv-aflibercept in retinal vascular diseases
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generally a significant reduction in average IOP over the study period, the averages fluctuated
over the study period (Table 3 and Fig 2).
No incidence of blurred vision, intraocular inflammation, cataract or endophthalmitis after
the injection were observed in any study eyes throughout the study. No systemic adverse
events were recorded. There was no significant difference in the fasting blood sugar, fasting
lipids (total cholesterol and LDL cholesterol), blood pressure (systolic and diastolic) at any
visit compared to baseline, and between the 2 groups (Table 3).
Visual outcome
The average BCVA (LogMAR) level for the study period was 0.7 ± 0.5. The mean BCVA (Log-
MAR) (±SD) at baseline, day 1 and 7 and at 4, 8 and 12 weeks were 0.9 ± 0.6, 0.9±0.6, 0.9±0.5,
0.6±0.4, 0.5±0.3, and 0.5±0.3. The Repeated-Measures ANOVA with nesting test showed that
the mean BCVA (LogMAR) did not vary significantly between the two IVZ doses but varied
significantly across the study time period (P<0.01). Over the study period, average BCVA
Table 1. Baseline characteristics of 20 eyes on treatment with intravitreal ziv-aflibercept.
Parameter IVZ 1.25mg (n = 10) IVZ 2mg (n = 10) P value
Age in complete years: Mean ± SD 63.0 ±6.7 63.4 ±8.4 0.91
Study eye right/left 5/5 (100%) 4/6 (100%) 1.00 1
Sex: male/female 4/6 (100%) 5/5 (100%) 1.001
Lens status: phakia/pseudophakia 9/1 (100%) 9/1 (100%) 1.00 1
PVD: yes/no 1/9 (100%) 1/9 (100%) 1.00 1
Main presenting complaint
Blurred vision 8 (80%) 10 (100%) 0.47 1
metamorphopsia 2 (20%) 0
Duration of symptoms: Mean ± SD 81.0±42.5 119.8±84.8 0.21
Diagnosis (number) 0.50™
Diabetic macular oedema 3 (30%) 2 (20%)
Neovascular AMD 3 (30%) 4 (40%)
CME secondary to RVO 4 (40%) 4 (40%)
Systemic co-morbidities, yes/no
Diabetes mellitus 5/5 (100%) 4/6 (100%) 0.301
Hypertension 8/2 (100%) 9/1 (100%) 1.001
Hyperlipidemia 2/8 (100%) 1/9 (100%) 1.00 1
Sickle cell 1/9 (100%) 0/10 (100%) 0.451
Blood pressure, mmHg
Systolic: Mean ± SD 144±17.1 142.2±22.4 0.84
Diastolic: Mean ± SD 83.5 ±6.7 81.6 ±11.8 0.66
Fasting lipids (LDL-CHOL): Mean ± SD 3.5 ±0.82 3.11 ±0.75 0.28
Fasting blood sugar, mmol/l: Mean ± SD 7.2 ±4.2 6.5 ±1.9 0.64
Visual acuity, LogMAR: Mean ± SD 1.0 ±0.6 0.85 ±0.6 0.49
Central subfield fovea thickness(um): Mean ± SD 382.2 ±128.4 429.6±153.8 0.46
central fovea thickness: Mean ± SD 435.6±201.8 386.2±153.5 0.54
Intraocular pressure: Mean ± SD 16.1±3.3 15.2±2.9 0.52
™ = chi square,
1 = Fischer’s exact test, AMD = age related macular degeneration, CME = cystoid macular edema, LDL-CHOL = low
density lipoprotein cholesterol, LogMAR = logarithm of minimum angle of resolution, n = number, SD = standard
deviation.
https://doi.org/10.1371/journal.pone.0223944.t001
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(LogMAR) improved marginally from baseline to Day 7 after which it improved drastically as
shown in Fig 2. Interaction between IVZ dose and study time period was not statistically sig-
nificant (Table 3). No eye had worsening of BCVA compared to baseline at any visit.
Anatomic outcome
The overall average CSFT (± SD) for the whole study period was 288.4 ± 114.6 μm. Mean
CSFT (± SD) at baseline, day 7, 4, 8 and 12 weeks were 405.9 ± 140μm, 306.7 ± 87.4μm,
255.7 ± 75μm, 238.6 ± 76μm and 238 ± 87.9μm, respectively. Generally, there was significant
reduction in the average CSFT (± SD) over the study period from 405.9 ± 140μm at baseline to
238 ± 87.9μm after 12 weeks (p<0.0001) however there was no significant variation between
the IVZ dose and interaction (IVZ dose and time) (Table 3 and Fig 2). No disparities occurred
in image grading/analysis that required adjudication.
Of the 7 eyes with nvAMD, there was significant reduction in the mean CSFT from
281.6 ±105μm at baseline to 197±46μm (p = 0.03) and 188.4 ±86μm (p = 0.02) at 4 and 12
weeks respectively. Similarly, of the 7 eyes with MO associated with RVO, there was significant
reduction in the mean CSFT to 255.9 ±56 μm (p<0.01) and 225.1 ±23 μm (p<0.01) at 4 and
12 weeks respectively compared to 488.4 ±124 μm at baseline. Of the 6 eyes with DMO, there
was significant reduction in the mean CSFT to 323.8 ±67 μm and 310.7 ±99 μm at 4 and 12
weeks respectively compared to 454.7 ±93 μm at baseline. Images of a case of nvAMD in the
right eye is shown in Fig 3.
Discussion
In this prospective randomized double-blind intervention study, no difference in ocular and
systemic adverse events, and the anatomic and visual outcome were found between the 1.25mg
and 2mg doses of IVZ at 4 and 12 weeks in treatment naïve eyes of Ghanaian patients with
DMO, nvAMD and MO following RVO. Specifically, no significant difference was observed in
eyes receiving the 2mg compared to 1.25mg of IVZ as would be expected from the larger vol-
ume administered with the higher drug dose.
Table 2. Ocular and systemic adverse events by treatment group.
Adverse event Group 1, IVZ 1.25mg Group 2, IVZ 2mg
Number of eyes = 10 Number of eyes = 10
Mild Moderate severe Mild moderate Severe
Ocular
Blurred vision 0 0 0 0 0 0
Pain 2 (20%) 0 0 1(10%)
Subconjunctival hemorrhage 1 (10%) 0 0 0 0
Cornea abrasions 0 0 0 0 0 0
IOP>21mmHg¥ 2 (20%) 0 0 5 0 0
Ocular Inflammation 0 0 0 0 0 0
Endophthalmitis 0 0 0 0 0 0
Retinal breaks/detachment 0 0 0 0 0 0
Systemic
Hypertension, hyperglycemia, chest pain, CCF, Infections, APTC-EVENTS, Death 0 0 0 0 0 0
Severity of adverse events is based on toxicity (adverse events) grading scale (S1 Table).
¥ = IOP>21mmHg was detected 30 minutes post injection only. APTC- antiplatelet trialists’ collaboration events (non-fatal myocardial infarctions, non-fatal strokes, or
vascular deaths), CCF = congestive cardiac failure, IOP = intraocular pressure.
https://doi.org/10.1371/journal.pone.0223944.t002
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Table 3. Comparison of changes in continuous variables between IVZ dose at baseline and up to 12 weeks visit using Repeated-Measures ANOVA with nesting.
Variable IVZ 1.25mg IVZ 2mg Overall P-value� P-value�� P-value���
Mean ± SD Mean ± SD Mean ± SD
Systolic BP, mmHg 140.1 ± 16.3 135.1 ± 17.3 137.6 ± 16.9
Baseline 144 ± 17.1 142.2 ± 22.4 143.1 ± 19.5 0.50 0.08 0.45
Day 1 140.1 ± 17.7 135 ± 17.8 137.6 ± 17.4
Day 7 142.8 ± 14.4 128.8 ± 10.9 136.2 ± 14.4
4weeks 141.8 ± 17.7 133.5 ± 14.5 137.7 ± 16.3
8weeks 136.1 ± 17.8 133.1 ± 15.6 134.6 ± 16.3
12weeks 136 ± 14.9 136.5 ± 20.6 136.3 ± 17.5
Diastolic BP, mmHg 83.2 ± 6.7 79.5 ± 11.3 81.4 ± 9.7 0.38 0.03 0.93
Baseline 83.5 ± 6.7 81.6 ± 11.8 82.6 ± 9.4
Day 1 84.9 ± 6.7 82 ± 12.3 83.5 ± 9.7
Day 7 85.6 ± 4.6 80 ± 12 82.9 ± 9
4weeks 82.5 ± 7.2 79 ± 13.1 80.8 ± 10.4
8weeks 81.5 ± 8.8 76.3 ± 11 78.9 ± 10.1
12weeks 81.5 ± 5.8 78 ± 12.3 79.8 ± 9.5
Fasting blood sugar 6.1 ± 2.7 6.4 ± 2.0 6.3 ± 2.4 0.75 0.22 0.34
Baseline 7.2 ± 4.2 6.5 ± 1.9 6.8 ± 3.2
Day 1 5.5 ± 1 6.1 ± 1.4 5.8 ± 1.2
Day 7 5.7 ± 1 6.7 ± 2.7 6.2 ± 2
Fasting Lipids Total Cholesterol 5.4 ± 0.8 5.0 ± 0.9 5.2 ± 0.9 0.39 0.72 0.46
Baseline 5.5 ± 1 5.1 ± 1 5.3 ± 1
Day 1 5.5 ± 0.8 5 ± 0.7 5.3 ± 0.8
Day 7 5.1 ± 0.5 4.9 ± 1.2 5 ± 0.9
Fasting lipids LDL 3.4 ± 0.8 2.9 ± 0.7 3.1 ± 0.7 0.35 0.14 0.72
Baseline 3.5 ± 0.8 3.1 ± 0.8 3.3 ± 0.8
Day 7 3.1 ± 0.6 2.7 ± 0.5 2.9 ± 0.5
BCVA, LogMAR 0.8 ± 0.5 0.7 ± 0.5 0.7 ± 0.5 0.46 <0.01 0.79
Baseline 1 ± 0.6 0.8 ± 0.6 0.9 ± 0.6
Day 1 1 ± 0.6 0.8 ± 0.6 0.9 ± 0.6
Day 7 0.9 ± 0.5 0.9 ± 0.5 0.9 ± 0.5
4weeks 0.7 ± 0.4 0.5 ± 0.3 0.6 ± 0.4
8weeks 0.6 ± 0.3 0.5 ± 0.3 0.5 ± 0.3
12weeks 0.5 ± 0.3 0.4 ± 0.3 0.5 ± 0.3
IOP, mmHg 15.2 ± 3.4 16.4 ± 3.9 15.8 ± 3.7 0.29 <0.01 0.85
Baseline 15.2 ± 2.9 16.1 ± 3.3 15.7 ± 3.1
30 minutes 18.5 ± 3 20.8 ± 4.6 19.7 ± 4
Day 1 14 ± 3.5 15.2 ± 3.1 14.6 ± 3.3
Day 7 13.7 ± 2.8 14.4 ± 3.4 14 ± 3
4weeks 15.2 ± 3.2 16 ± 3.7 15.6 ± 3.4
8weeks 13.6 ± 2.2 15.6 ± 3.4 14.6 ± 2.9
12weeks 15.9 ± 3.9 16.6 ± 3 16.3 ± 3.4
CSFT, um 263.3 ± 106.4 314 ± 118.1 288.4 ± 114.6 0.16 <0.01 0.91
Baseline 382.2 ± 128.4 429.6 ± 153.8 405.9 ± 140
Day 7 284.7 ± 88.5 331.5 ± 84.8 306.7 ± 87.4
4weeks 222.9 ± 56.9 288.4 ± 79.1 255.7 ± 75
8weeks 213.3 ± 69 263.8 ± 77.5 238.6 ± 76
12weeks 215.7 ± 75.5 260.2 ± 97.5 238 ± 87.9
(Continued)
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Ziv-aflibercept and aflibercept are identical fusion proteins comprising of the Fc portion of
human immunoglobin IgG1 and extracellular matrix domains of VEGF receptors 1 and 2
[15]. They act as decoy receptors by binding to circulating VEGF- A and B and placental
growth factor. Ziv-aflibercept is an 115kDa molecule manufactured from Chinese hamster
Table 3. (Continued)
Variable IVZ 1.25mg IVZ 2mg Overall P-value� P-value�� P-value���
Mean ± SD Mean ± SD Mean ± SD
CFT, um 248.6 ± 124.2 302.8 ± 147.1 275.4 ± 138 0.19 <0.01 0.62
Baseline 387.3 ± 156 429.8 ± 193.3 408.6 ± 172.4
Day 7 264.7 ± 116.2 346.1 ± 122.6 303 ± 122.8
4weeks 202.9 ± 69.7 271 ± 97.2 237 ± 89.5
8weeks 199 ± 77.1 234.7 ± 96.3 216.9 ± 86.8
12weeks 190.5 ± 68.7 240.8 ± 122.8 215.7 ± 100.2
�P-value: P-value from ANOVA test for comparing means between drug dose,
��P-value: p-value from Huynh-Feldt epsilon for comparison of means over time period,
���P-value: p-values from Huynh-Feldt epsilon for comparison of means over drug dose and time period drug (interaction). BCVA = best corrected visual acuity, BP
blood pressure, CFT = central fovea thickness, CSFT = central subfield fovea thickness, FBS = fasting blood sugar, IOP = intraocular pressure, LogMAR = logarithm of
minimum angle of resolution, LDL = low density lipoprotein, CHOL = cholesterol, mmol/L = millimole per litre, SD = standard deviation.
https://doi.org/10.1371/journal.pone.0223944.t003
Fig 2. Mean change in clinical parameters over time with 2 standard error margin. 1 = baseline, 2 = 30 minutes post-injection,
3 = day 1, 4 = day 7, 5 = 4 weeks, 6 = 8 weeks, 7 = 12 weeks, BCVA = best corrected visual acuity, CSFT = central sub-field fovea
thickness, dbp = diastolic blood pressure, fbs = fasting blood sugar, IOP = intraocular pressure, sbp = systolic blood pressure.
https://doi.org/10.1371/journal.pone.0223944.g002
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ovary cells [15]. The molecular structure of ziv-aflibercept is identical to aflibercept. However,
the 2 drugs are different because they undergo different purification processes, and whilst afli-
bercept is iso-osmotic (300mosm/kg) ziv-aflibercept is hyperosmotic (1000mosm/kg) due to
addition of higher concentration of sucrose [15, 23]. Ziv-aflibercept is packaged as 25mg/ml of
ziv-aflibercept in polysorbate 20 (0.1%), sodium citrate (5 mM), sodium phosphate (5 mM)
and sucrose (20%), in water for Injection USP, at a pH of 6.2 and aflibercept as 40mg/ml afli-
bercept in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5%
sucrose, pH 6.2 [15]. Aflibercept has been approved by the USA FDA for ocular use whilst ziv-
aflibercept was approved for the treatment of metastatic colorectal cancers and other cancers
[7]. There had been earlier concerns about the intravitreal administration of ziv-aflibercept
due to hyper-osmolality, but the potential retinal toxicity from its hyper-osmolality has been
refuted by several studies [12, 15, 18, 24–30]. Malik et al has shown that the use of 1.25mg and
2mg doses of ziv-aflibercept did not affect the viability of human retinal pigment epithelial
cells in vitro although there was a mild reduction in mitochondrial membrane potential with
the 2mg dose [31]. Similarly, de Oliveira Dias (2015) reported that ziv-aflibercept was safe in
the rabbit eye when given intravitreally in doses up to 25mg/ml [32]. Mansour et al (2015) and
Chhablani et al (2016) reported that the intravitreal administration of 1.25mg of ziv-aflibercept
did not show ocular toxicity at 4 weeks in eyes with DMO and nvAMD [12, 15]. In the present
Fig 3. Fundus photograph (CFP), fluorescein angiogram (FFA) and spectral domain optical coherence tomography (SD-OCT) of a 56-year
female presenting with metamorphosia in the right eye of 2 months’ duration. CFP (A and B) shows drusen and reticular pseudodrusen (RPD) in
both eyes with subfoveal CNV in the right eye confirmed with FFA (C-F). SD-OCT showed vitreomacular adhesion (VMA), intraretinal (IRF) and
subretinal fluid (IRF) and retinal pigment epithelial detachment (PED) at baseline(G), with resolution of IRF and SRF at 4 (H) and 12 (weeks) and
separation of the VMA at 12 weeks (I). Visual acuity at baseline of 0.4 LogMAR improved to 0.24 LogMAR and 0.2 LogMAR at 4 and 12 weeks,
respectively.
https://doi.org/10.1371/journal.pone.0223944.g003
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study, 3 patients reported of mild pain on day 1 and 6 had elevation of IOP at 30 minutes post-
injection. The recommended dose of intravitreal aflibercept is 2mg/0.05ml. A higher volume
of ziv-aflibercept (2mg/0.08ml) is required to achieve same dose as aflibercept and can poten-
tially lead to a rise in IOP. Chhablani et al (2017) did not observe significantly raised IOP
(>21mmHg) at 30 minutes post-injection of 2mg IVZ [19]. However, 4 of the 21 eyes in their
study had anterior chamber paracentesis because digital examination suggested immediate
IOP increase [19]. In our study, we observe increased IOP>21mmHg in 5 eyes who received
2mg IVZ; however, none of the eyes had IOP increase beyond 10mmHg from baseline and the
elevation of IOP reverted to normal range without treatment. Intravitreal injections of pegap-
tanib (Macugen, Pfizer), the first anti-VEGF agent licensed for intraocular injection was
approved to be delivered at a dose of 0.3mg in 0.09ml of volume [33]. Although there was tran-
sient elevation of IOP, this did not translate into serious adverse events [34].
Although we did not observe significant difference in the visual and anatomic outcome
between the 1.25mg and 2mg dose of IVZ at 4 weeks and 12 weeks, the number of eyes in our
study was small but compatible with our primary focus to determine the safety of the 2 differ-
ent doses of IVZ in a Ghanaian population with DMO, nvAMD and RVO, but not powered
for efficacy. This corroborates the results of the three armed double blind study (which
included 123 eyes) of Baghi et al which did not observe significant difference in the visual and
anatomic outcome between eyes with DMO who received 1.25mg (42 eyes) versus 2.5mg (42
eyes) at 12 weeks(28) or study extension to 1 year [35]. Several short-term and a few long term
studies from other populations elsewhere have shown that the 1.25mg dose of IVZ was safe
and effective when administered to eyes with DMO, nvAMD and RVO [10–17]. The results
are supported by the recent retrospective study of Singh et al (2018) [20].
The limitations of our study are the inclusion of small number of eyes with varied clinical
diagnosis and short duration of follow-up. However, the primary focus of this study was to sys-
tematically evaluate the safety of the 2 different doses of IVZ in eyes with DMO, nvAMD and
RVO, as a prelude to further studies on efficacy. The doses chosen were limited by the concen-
tration of the commercially available ziv-aflibercept. As such a wider dose range was not possi-
ble as the drug volume delivered intravitreal would have resulted in potential under-dosing
(e.g. at 0.02 mls for a lower dose), or too large a volume (e.g. 0.15mls for a higher dose). The
efficacy and safety of IVZ in a Ghanaian population with retinal vascular diseases will need to
be confirmed through further studies with larger numbers and a longer duration of follow-up.
The other limitations of this study are that pharmacodynamic measurements and genetic test-
ing were not perfromed.
Conclusion
The 1.25mg and 2mg dose of ziv-aflibercept administered at 4-weekly intervals was found to
be safe up to 12 weeks in the eyes of Ghanaian Africans with DMO, nvAMD, and MO second-
ary to RVO. The adverse events observed were mild and resolved without treatment. There
was a tendency for improvement in BCVA at 12 weeks and reduction in CMT at 12 weeks. A
randomized prospective study which includes a larger number of participants evaluated over a
longer time period is required to verify our findings and establish the efficacy of IVZ in retinal
diseases in the African.
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